$2.2 Billion COVID Vaccine Case: Pfizer Wins Belgian Court Ruling

A Brussels court ruled on April 1, 2026 that Poland and Romania must fulfill their contractual obligations to purchase surplus COVID-19 vaccines from PFE, ordering the two countries to pay a combined approximately $2.2 billion. Poland faces the larger judgment at approximately $1.4 billion for roughly 60 million doses it refused to accept in April 2022, after invoking a contractual exit clause and citing declining infection rates and budget strain from the influx of Ukrainian refugees. Romania faces a separate approximately $660 million judgment for a comparable refusal to accept contracted vaccine doses.

The Brussels Court of First Instance ruled that neither country had demonstrated that Pfizer was abusing its contractual rights by pursuing payment enforcement. The suits were filed in fall 2023 and stem from the EU Commission's bulk vaccine purchasing arrangements made in 2020-2021, which locked member states into binding purchase commitments. Both Poland and Romania argued their pandemic circumstances had materially changed, but the court rejected those defenses.

For PFE investors, the ruling validates the enforceability of Pfizer's COVID-era vaccine contracts and could provide a template for pursuing similar claims against other EU member states that refused contracted deliveries. However, the financial impact is modest relative to Pfizer's total revenue base, and the company's more pressing narrative centers on new product launches and pipeline progression following the wind-down of its COVID vaccine and antiviral revenue cycle. The ruling is a legal win, not a commercial catalyst.